Active tuberculosis in psoriasis patients treated with TNF antagonists: a French nationwide retrospective study

Journal of the European Academy of Dermatology and Venereology

Volumn 30, Issue 8, 2016, Pages 1336-1341

  Guinard, E ^a   Bulai Livideanu, C ^a   Barthelemy H ^b   Viguier, M ^c   Reguiai, Z ^d   Richard, M A ^e,f   Jullien, D ^g   Beneton, N ^h   Bara, C ^h   Vabres, P ⁱ   Grandvuillemin, A ⁱ   Marguery, M C ^a   Amelot, F ^a   Konstantinou, M P ^a   Bagheri, H ^j   Paul, C ^a  

^a UNIVERSITÉ PAUL SABATIER   (France)

^b Service de dermatologie   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d REIMS UNIVERSITY HOSPITAL   (France)

^e AIX MARSEILLE UNIVERSITY   (France)

^f University of the Mediterranean Aix Marseille II   (France)

^g UNIVERSITÉ DE LYON   (France)

^h Service de Dermatologie   (France)

ⁱ DIJON UNIVERSITY HOSPITAL   (France)

^j TOULOUSE UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; CYCLOSPORIN; ETANERCEPT; ETRETIN; INFLIXIMAB; ISONIAZID; METHOTREXATE; RIFAMPICIN; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB;

ADULT; AGED; ARTICLE; BCG VACCINATION; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; LATENT TUBERCULOSIS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS TEST KIT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; RETROSPECTIVE STUDY; RISK FACTOR; SAPHO SYNDROME; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84987923875     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.13633     Document Type: Article

References (31)

1. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrotising factor-neutralizing agent. N Engl J Med 2001; 345: 1098–1104.
2. Xie X, Li F, Chen JW, Wang J. Risk of tuberculosis infection in anti TNF alpha biological therapy: from bench to bedside. J Microbiol Immunol Infect 2014; 47: 268–274.
3. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD; BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk. Arthritis Rheum 2003; 48: 2122–2127.
4. Dixon WG, Hyrich KL, Watson KD et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010; 69: 522–528.
5. Tubach F, Salmon D, Ravaud P et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective french research axed on tolerance biotherapies registry. Arthritis Rheum 2009; 60: 1884–1894.
6. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology. Arthritis Rheum 2006; 54: 2368–2376.
7. Baronnet L, Barnetche T, Kahn V, Lacoin C, Richez C, Shaeverbeke T. Incidence de la tuberculose chez les patients atteints de polyarthrite rhumatoïde. Revue systématique de la littérature. Rev Rhum 2011; 78: 140–146.
8. Afssaps. Prévention et prise en charge des tuberculoses survenant sous anti-TNFa. [WWW document] 2005. URL http://www.ansm.sante.fr/content/download/12022/143647/version/2/file/reco.pdf (last accessed: April 20, 2016).
9. Ormerod LP, Milburn HJ, Gillespie S, Ledingham J, Rampton D. BTS recommendations for assessing risk, and for managing M. tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 2005; 60: 800–805.
10. Dohert SD, Van Voorhes A, Lebwohl MG, Korman NJ, Young MS, Hsu S. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients treated with systemic and biologic agents. J Am Acad Dermatol 2008; 59: 219–217.
11. Fraisse P; Groupe tuberculose de la SPLF. Traitement des infections tuberculeuses latentes. Rev Mal Respir 2012; 29: 579–600.
12. HAS. Test de détection de la production d'IFN γ pour le diagnostic des infections tuberculeuses. [WWW document] 2006. URL http://www.has-sante.fr/portail/upload/docs/application/pdf/synthese_detection_de_linterferon-gamma.pdf (last accessed: April 20, 2016).
13. Lioté H, Lioté F. Place des tests à l'interféron (IGRAs) dans le dépistage de la tuberculose latente (TBL) avant prescription d'agents anti-TNF: le point. Rev Rhum 2011; 78: 116–121.
14. Mariette X, Lioté F, Goupille P et al. Le remplacement de l'intradermoréaction (IDR) à la tuberculine par les tests sanguins spécifiques permet de diviser par deux la fréquence de la tuberculose (TB) latente. Résultats de l'étude ETAT chez 369 patients avant mise sous anti-TNF. Rev Rhum 2010; 77: 37–38.
15. Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V et al. BIOBADASER Group. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52: 1766–1772.
16. Takeuchi T, Tatsuki Y, Nogami Y et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008; 67: 189–194.
17. European best practice guidelines for renal transplantation (expert group). Section IV: long-term management of the transplant recipient IV.7.2. Late infections. Tuberculosis. Nephrol Dial Transplant 2002; 17: 39–42.
18. Lioté H. Tuberculose, agents anti TNF et autres immunosuppresseurs: évolution des stratégies de prévention. Rev Mal Respir 2008; 10: 1237–1249.
19. Sayarlioglu M, Iranc C, Kamali S et al. Tuberculosis in Turkish patients with systemic lupus erythematosus: increased frequency of extrapulmonary localization. Lupus 2004; 13: 274–278.
20. Aguado JM, Herrero JA, Gavalda J et al. Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Spanish Transplantation infection Study group. GESIDRA. Transplantation 1997; 63: 1278–1286.
21. Centers for Disease Control and Prevention. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendation. MMWR Morb Mortal Wkly Rep 1998; 47:1–51.
22. Turunç T, Habeşoğlu MA, Demiroğlu YZ et al. Comparative evaluation of 113 cases with severe and mild forms of extrapulmonary tuberculosis. Mikrobiyol Bul 2008; 42: 399–406.
23. Lalvani A, Pareek M. Interferon gamma release assays: principles and practice. Enfer Infecc Microbiol Clin 2010; 28: 245–252.
24. Pai M, Denkinger CM, Kik SV et al. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev 2014; 27: 3–20.
25. Metcalfe JZ, Everett CK, Steingart KR et al. Interferon-gamma release assays for active pulmonary tuberculosis diagnosis in adults in low- and middle-income countries: systematic review and meta-analysis. J Infect Dis 2011; 204(Suppl 4): 1120–1129.
26. Yong-Soo K, Yee Hyung K, Kyeongman J et al. Factors that predict negative results of QuantiFERON- TB gold in-tube test in patients with culture-confirmed tuberculosis: a multicentre retrospective cohort study. PLoS ONE 2015; 10: e0129792.
27. Jung JY, Lim JE, Lee HJ et al. Questionable role of interferon-gamma assays for smear-negative pulmonary TB in immunocompromised patients. J Infect 2012; 64: 188–196.
28. Matulis G, Juni P, Villiger PM, Gadola SD. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay. Ann Rheum Dis 2008; 67: 84–90.
29. Perez J, Kupper H, Radin A, Spencer-Green G. Impact of screening for latent TB prior to initiating anti-TNF therapy. [Abstract] Ann Rheum Dis 2005; 64 (Suppl 3):265.
30. Ergun T, Seckin D, Baskan Bulbul E et al. The risk of tuberculosis in patients with psoriasis treated with anti-tumor necrosis factor agents. Int J Dermatol 2015; 54: 594–599.
31. HAS. Commission de la transparence. [WWW document] 2008. URL http://www.has-sante.fr/portail/upload/docs/application/pdf/2008-06/ct-5381_humira_.pdf (last accessed: April 20, 2016).